Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples